Regeneron's cemdisiran, a potential first siRNA therapy for generalized myasthenia gravis (gMG), has been accepted for regulatory review by the FDA and EMA. The FDA is conducting a Priority Review with a decision expected by November 2026, while the European Commission's decision is anticipated in the second half of 2027. Cemdisiran is administered subcutaneously every 12 weeks and targets patients with anti-AChR antibody-positive gMG, offering a novel treatment option with less frequent dosing. This follows positive Phase 3 trial results from the NIMBLE study, addressing a significant unmet need in managing this rare autoimmune disease.
Regeneron Pharmaceuticals will announce its financial and operating results for the second quarter of 2026 on July 30, before U.S. markets open. The company will hold a conference call and webcast at 8:30 AM Eastern Time the same day, accessible via ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
